DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/24c5v2/future_prospects) has announced the addition of the "Future Prospects of Global Personalized Medicine Market 2012-2016" report to their offering.

The Global Personalized Medicine market 2012-2016 to grow at a CAGR of 12.07 percent over the period 2012-2016.

One of the key drivers in this market is the significant growth of the Targeted Biologics segment. This segment is one of the significant segments of personalized medicine and is expected to signify about 25 percent of the commercialized drugs during the forecast period.

Over the years, the Global Personalized Medicine market has been witnessing the emergence of various tools and technologies from the reputed vendors. For instance, AssureRx Health Inc. launched GeneSightRx ADHD in May 2012, a personalized medicine test for the growing number of children and adults diagnosed with ADHD. Moreover, Bristol-Myers Squibb Co. collaborated with MMRF in December 2012 for advanced personalized medicine for multiple Myeloma. Further, Alacris Theranostics GmbH entered into an agreement with GlaxoSmithKline plc in November 2012 to use ModCell system for early stage cancer research. Further, AltheaDx Inc. launched FLT3 Mutation Assay in October 2012. Agendia N.V. launched ColoPrint microarray-based 18-gene expression signature in June 2012 for predicting the risk of distant recurrence for stage II colon cancer patients. The European Medicines Agency approved Zelboraf, manufactured by F. Hoffmann-La Roche Ltd., in December 2011.

Further, the report states that one of the major challenges is patients' limited awareness about personalized medicines in developing countries. Most of the patients in developing countries such as India and China are not fully aware of the recent developments in personalized medicines.

The key vendors dominating this space include:

Key Topics Covered:

01. Executive Summary

02. List of Abbreviations

Read more here:

Research and Markets: Global Personalized Medicine Market to 2016: Abbott, AstraZeneca, F. Hoffman-La Roche, Novaris ...